Cangene Corp. (CNJ.TO)
-Toronto 2.65 
0.25(10.42%) Jun 18
| Prev Close: | 2.40 |
|---|
| Open: | 2.58 |
|---|
| Bid: | 2.51 |
|---|
| Ask: | 2.65 |
|---|
| 1y Target Est: | 2.60 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.58 - 2.65 |
|---|
| 52wk Range: | 1.40 - 3.28 |
|---|
| Volume: | 13,080 |
|---|
| Avg Vol (3m): | 15,381 |
|---|
| Market Cap: | 176.88M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in CAD.
Headlines
- Canada Stocks to Watch: Sears Canada, Cameco and Moreat The Wall Street Journal(Fri, Jun 14)
- Cangene Announces Withdrawal of Marketing Authorization Application for Investigational Hemophilia Compound IB1001 in EuropeCNW Group(Thu, Jun 13)
- Canada Stocks to Watch: Dominion Diamond, Brick, Bombardier and moreat The Wall Street Journal(Thu, Jun 6)
- Cangene Reports Third Quarter 2013 ResultsCNW Group(Wed, Jun 5)
- Canada Stocks to Watch: RIM, AltaGas, Cangene and moreat The Wall Street Journal(Mon, Mar 25)
- CANADA STOCKS-TSX may open higher on Cyprus bailout dealat Reuters(Mon, Mar 25)
- Cangene announces FDA approval of Botulism AntitoxinCNW Group(Mon, Mar 25)
- U.S. FDA approves Cangene's treatment for botulismat Reuters(Fri, Mar 22)
- Cangene Wins U.S. FDA Approval for Antidote to Botulismat Bloomberg(Fri, Mar 22)
- Cangene Reports Second Quarter 2013 ResultsCNW Group(Wed, Mar 13)
- FFF Enterprises Named Exclusive Distributor of Cangene's VARIZIG(R)Marketwired(Thu, Feb 28)
- Cangene Advances Alzheimer's Disease Research with Technology Developed at the University of British ColumbiaCNW Group(Thu, Feb 21)
- FDA Advisory Committee Votes in Favour of Cangene's Botulism Antitoxin ProductCNW Group(Tue, Feb 12)
- Cangene Antidote for Bioterror Toxin Wins Advisers’ Supportat Bloomberg(Tue, Feb 12)
- Inspiration sells off remaining hemophilia drug assets, prepares to liquidateat bizjournals.com(Wed, Feb 6)
Key Statistics
| Forward P/E (1 yr): | 22.08 |
|---|
| P/S (ttm): | 1.22 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jul-13)
: | 0.06 |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cangene Corporation, a biopharmaceutical company, develops, manufactures, and commercializes immune therapeutics primarily in Canada and the United States.
View More